Phase I study of combination topotecan and carboplatin in pediatric solid tumors

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 88-95

  Athale, Uma H ^a   Stewart, Clinton ^a   Kuttesch, John ^a   Moghrabi, Albert ^a   Meyer, William ^a   Pratt, Charles ^a   Gajjar, Amar ^a   Heideman, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFANT; LIKELIHOOD FUNCTIONS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; SALVAGE THERAPY; TOPOTECAN;

EID: 0036140067     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.88     Document Type: Article

References (45)

1. Common solid tumors of childhood
2. Carboplatin and recurrent childhood brain tumors
3. Phase I study of carboplatin (CBDCA) in children with cancer
4. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study
5. Carboplatin in childhood brain tumors: A Children's Cancer Study Group phase II trial
6. Etoposide and carboplatin in neuroblastoma: A French Society of Pediatric Oncology phase II study
7. Phase study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors
8. "JEB": A carboplatin based regimen for malignant germ cell tumors in children
9. Escalating sequential high dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors
10. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors
11. Carboplatin versus cisplatin in solid tumors: An analysis of literature
12. Preclinical antitumor and toxicology profile of carboplatin
13. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers
14. Topotecan today
15. Platinum analogues
16. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
17. Controlling carboplatin pharmacokinetic variability in pediatric cancer patients
18. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
19. DNA topoisomerase poisons as antitumor drugs
20. The current status of camptothecin analogues as antitumor agents
21. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
22. Evaluation of 9-dimethylamino-10-hydroxycamptothecan against xenografts derived from adults and childhood solid tumors
23. Antitumor activity of camptothecin derivative, CPT-11, against human xenografts in nude mice
24. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia
25. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
26. Phase I study of topotecan for pediatric patients with malignant solid tumors
27. NCI common toxicity criteria, version 1
28. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
29. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer
30. Combination regimens with topotecan in animal tumor models
31. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
32. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
33. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer
34. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
35. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays
36. Schedule dependency of carboplatin and topotecan: Phase I pharmacokinetic studies
37. O6-alkylation of guanine induces topoisomerase I-DNA covalent complexes in vitro and in MNNG-treated cells
38. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence dependent hematologic side effects
39. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38 in human small cell lung cancer cells
40. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro
41. Cellular pharmacology of the combination of the DNA topisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin
42. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence
43. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line